Haha Drongo. I guess you have been caught on the wrong side this time. BCRX has been a nightmare for shorts for the last 6 months and it's just getting worse. I shouldn't really enjoy your suffering, but there is just something delicious about those who bet on failure getting their comeuppance.
Next up is publication of data on 4430 which DOD officials have already referred to most glowingly. Soon after that will be the first news/comments on the HAE P2 Trial. [and lets hope there isn't a 2009 style flu season (or more bird flu), 'cause then you will see how the medical establishment values the efficacy of Peramivir]
You better keep trying desperately to scare people into selling their BCRX now because it is only going to get worse. 3 pages of posts from your three day old alias... reeks your desperation.
There was good efficacy shown in the P2s and in the P2s and P3s in Japan (flu capital of the world).
In this trial it was given to hospitalized patients they could find who hadn't already been given tamiflu. – Bottom line, it was administered too late to be effective
Ballsy move. I would have preferred the outcome that DavidDoc parodied Lennon in earlier today. I think momentum is definitely with BCRX at the moment, and with a series of news bites to come over the next weeks, and months.
Up 6% in pre market, but not on huge volume. Should be a nice day at least – remember, they have been stating and confirming that the NDA would be filed this quarter for over 6 months now – so it is not really news.
The only people who doubted were Wood and that TottenhamDrongo.
Hey Prop... did you send it to: husys4u2 at yahoo 'cause that was a typo (no "K"). He is: huskys4u2 at yahoo
A bit premature Totten. Make your crowing posts if we hit Dec 31st with no filing. You will just look foolish when it happens before then (as scheduled) after posting rubbish like this.
Of course what do you care - and irrelevant alias made up recently and soon to be discarded - your comments are weighted accordingly.
Haha, just teasing ya Husky. You are an early riser for sure.
The stock doesn't know where it wants to be this a.m. I think it will end up slightly green. I'm still picking tomorrow as the filing for "P." Even though that shouldn't be news, it could be worth quite a bump (if you consider that we all knew that HAE mark 2 was going into preclinical this month, yet we got a nice push when it happened).
Analyst Brian Abrahams said, "While the second generation compounds are still at an early preclinical stage, PK profiles of the compounds look promising, suggesting that they could potentially further improve upon '4161's profile (and IP) and help the longterm life cycle management of the company's potential HAE franchise. We continue to believe '4161's proofofconcept study (OPuS1), expected to read out by mid2014, has a good probability of success, and that BCRX shares undervalue the potential HAE opportunity on a risk/reward basis."
Wells Fargo maintained an Outperform rating on BioCryst Pharma (NASDAQ: BCRX). Comments follow news BioCryst has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) attacks.
There is no "appears" about it Joe. Management was very clear (back when they used to actually comment about Ulodesine) that they were not going to move ahead alone. The mentioned ongoing talks at the next CC after that, and then never mentioned it again. I fear the worst.
It is like finding out that "good-times" Uncle Franz was a #$%$ war criminal... and now the family pretends he never existed
They stopped talking about Gout almost two years ago, and have been pretending it doesn't exist. So weird.
"Push through $7... Push through $7... Push through $7... Push through $7... Push through $7... "
Hey Not a Doc (formally known as a Doc), I'm referring to your comment the other day about popping on 'no news'
This is no news. While obviously an important milestone, the 2nd gen HAE molecules are no secret and Stony had told the world several times that they were being advanced into pre-clinical before the end of the year. [Actually, on the last CC I think he said they would be advancing 3 molecules before the end of the year, but I might be "misremembering"]
I agree with you on that. The index news is 'itty bitty' – some off the big pennies to drop should have a dramatic effect.
" it been said time after time on this board that the HAE community will be providing incidental reports on trial subjects... "
I usually get to read most posts on this board (though I do have a number of people on ignore), and I have not seen "time after time" postings about this at all.
I personally don't expect any useful HAE trial info for months.
To be fair:
"The study looked at the potential of lesinurad as a monotherapy in the small number of gout patients who are intolerant to, or otherwise cannot take, the xanthine oxidase inhibitor drugs allopurinol and febuxostat."
So it may be just these hyper sensitive patients. If the same thing shows up in any of the 3 other P3 trials then it might be the death knoll.